Clinical Trial Update: Efficacy of Tezepelumab in Peanut Oral Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tezepelumab for peanut oral immunotherapy is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Peanut Allergy | Phase 2 | Status: NOT_YET_RECRUITING